Could Newer Treatments Used As Frontline Treatment Decrease Future Efficacy of FCR?

Could using newer treatments, like ibrutinib (Imbruvica), as a frontline treatment decrease the future efficacy of FCR if the patient becomes refractory? CLL expert Dr. Jeff Sharman shares his insights and the role of biomarkers, including IGHV and FISH.

Get email alerts | http://www.patientpower.info/alerts

Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo